[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA50674B1 - Benzamides substitués 1,3-thiazol-2-yl - Google Patents

Benzamides substitués 1,3-thiazol-2-yl

Info

Publication number
MA50674B1
MA50674B1 MA50674A MA50674A MA50674B1 MA 50674 B1 MA50674 B1 MA 50674B1 MA 50674 A MA50674 A MA 50674A MA 50674 A MA50674 A MA 50674A MA 50674 B1 MA50674 B1 MA 50674B1
Authority
MA
Morocco
Prior art keywords
thiazol
substituted benzamides
benzamides
substituted
Prior art date
Application number
MA50674A
Other languages
English (en)
Other versions
MA50674A (fr
Inventor
Adam Davenport
Nico Bräuer
Oliver Martin Fischer
Andrea Rotgeri
Antje Rottmann
Ioana Neagoe
Jens Nagel
Anne-Marie Godinho-Coelho
Jürgen Klar
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52015966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50674(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MA50674A publication Critical patent/MA50674A/fr
Publication of MA50674B1 publication Critical patent/MA50674B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MA50674A 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl MA50674B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196954 2014-12-09

Publications (2)

Publication Number Publication Date
MA50674A MA50674A (fr) 2021-03-31
MA50674B1 true MA50674B1 (fr) 2022-11-30

Family

ID=52015966

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41135A MA41135B1 (fr) 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl
MA50674A MA50674B1 (fr) 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA41135A MA41135B1 (fr) 2014-12-09 2015-12-07 Benzamides substitués 1,3-thiazol-2-yl

Country Status (42)

Country Link
US (5) US10174016B2 (fr)
EP (2) EP3587417B9 (fr)
JP (2) JP6544665B2 (fr)
KR (2) KR102548799B1 (fr)
CN (2) CN107207507B (fr)
AR (2) AR102948A1 (fr)
AU (1) AU2015359626B2 (fr)
BR (1) BR112017012327B1 (fr)
CA (1) CA2969952A1 (fr)
CL (1) CL2017001488A1 (fr)
CO (1) CO2017005742A2 (fr)
CR (2) CR20210108A (fr)
CU (1) CU24411B1 (fr)
CY (2) CY1124486T1 (fr)
DK (2) DK3587417T3 (fr)
DO (2) DOP2017000137A (fr)
EA (2) EA034273B1 (fr)
EC (1) ECSP17036253A (fr)
ES (2) ES2908822T3 (fr)
HR (2) HRP20220371T1 (fr)
HU (2) HUE058009T2 (fr)
IL (6) IL252665B (fr)
JO (1) JOP20150301B1 (fr)
LT (2) LT3230281T (fr)
MA (2) MA41135B1 (fr)
MX (2) MX2020005909A (fr)
MY (1) MY192690A (fr)
NI (1) NI201700073A (fr)
NZ (1) NZ761161A (fr)
PE (2) PE20220253A1 (fr)
PH (1) PH12017501079A1 (fr)
PL (2) PL3587417T3 (fr)
PT (2) PT3587417T (fr)
RS (2) RS62227B1 (fr)
SG (2) SG11201704717VA (fr)
SI (2) SI3230281T1 (fr)
SV (1) SV2017005461A (fr)
TN (1) TN2017000244A1 (fr)
TW (2) TWI780562B (fr)
UA (1) UA120382C2 (fr)
UY (1) UY36422A (fr)
WO (1) WO2016091776A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6544665B2 (ja) * 2014-12-09 2019-07-17 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １，３−チアゾール−２−イル置換ベンズアミド
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN106588785A (zh) * 2016-12-02 2017-04-26 山东吉田香料股份有限公司 一种乙酰基吡嗪的制备方法
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
EP3793554A1 (fr) * 2018-05-15 2021-03-24 Bayer Aktiengesellschaft Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses
MX2020012230A (es) * 2018-05-15 2021-01-29 Bayer Ag Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas con la sensibilizacion de las fibras nerviosas.
PL3862000T3 (pl) 2018-10-05 2024-03-18 Shionogi & Co., Ltd Lek na przewlekły kaszel
WO2020074962A1 (fr) * 2018-10-10 2020-04-16 Bellus Health Cough Inc. Traitement du prurit avec des antagonistes des récepteurs p2x3
CA3131312A1 (fr) * 2019-02-25 2020-09-03 Bellus Health Cough Inc. Traitement avec des modulateurs de p2x3
CN113661165A (zh) * 2019-04-05 2021-11-16 先正达农作物保护股份公司 杀有害生物活性的二嗪-酰胺化合物
US20220169629A1 (en) * 2019-04-11 2022-06-02 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
MA56020A (fr) 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés de pyridopyrimidines utilisés en tant qu'inhibiteurs de p2x3
AU2020281923A1 (en) 2019-05-31 2022-01-06 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as P2X3 inhibitors
EP3757103A1 (fr) * 2019-06-27 2020-12-30 Bayer AG Analogues de 3-(5-méthyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}benzamide pour le traitement des maladies neurogeniques
CN113082023B (zh) * 2019-12-23 2024-03-01 武汉朗来科技发展有限公司 P2x3抑制剂和p2x4抑制剂的药物组合及其应用
WO2021238834A1 (fr) * 2020-05-25 2021-12-02 中国医药研究开发中心有限公司 Composé arylformamide et son procédé de préparation et son utilisation médicale
WO2022063205A1 (fr) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 Composé aryl formamide, son procédé de préparation et ses utilisations médicales
KR20230065303A (ko) * 2020-09-30 2023-05-11 휴먼웰 헬스케어 (그룹) 씨오. 엘티디. 벤즈아미드계 화합물 및 이의 용도
MX2023005801A (es) 2020-11-27 2023-05-29 Chiesi Farm Spa Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
EP4251620A1 (fr) 2020-11-27 2023-10-04 Chiesi Farmaceutici S.p.A. Dérivés d'amino-quinazoline utilisés en tant qu'inhibiteurs de p2x3
MX2023005805A (es) 2020-11-27 2023-06-01 Chiesi Farm Spa Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
WO2022253943A1 (fr) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Formes cristallines de 3-(5-méthyl-1,3-thiazol-2-yl)-5-[(3r)-tétrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}-benzamide
WO2022253945A1 (fr) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Formes posologiques pharmaceutiques comprenant du 3-(5-méthyl-1,3-thiazol-2-yl)-5-[(3r)-tétrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluorométhyl)pyrimidin-5-yl]éthyl}-benzamide
US12024285B1 (en) 2022-03-10 2024-07-02 Skypad Tech, Inc. Modular mobility system including thrusters movably connected to a support structure
KR20240154068A (ko) 2022-03-29 2024-10-24 휴먼웰 헬스케어 (그룹) 씨오. 엘티디. P2x3 억제제 화합물 및 이의 염, 다형체 및 용도
CN118239941A (zh) * 2022-12-22 2024-06-25 人福医药集团股份公司 制备p2x3抑制剂的方法
CN117777048B (zh) * 2023-09-25 2024-09-20 上海科利生物医药有限公司 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5198256B2 (ja) 2005-05-04 2013-05-15 エボテク エージー 縮合複素環式化合物、並びにそれらの組成物及び使用
JP5021734B2 (ja) 2006-06-29 2012-09-12 エフ．ホフマン−ラ ロシュ アーゲー テトラゾール置換アリールアミド
ATE517097T1 (de) 2006-11-09 2011-08-15 Hoffmann La Roche Thiazol- und oxazolsubstituierte arylamide
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
JP5396379B2 (ja) 2007-04-02 2014-01-22 エボテック・アーゲー ピリド−２−イル縮合複素環式化合物ならびにその組成物および使用
EP2139334B1 (fr) 2007-04-17 2013-07-03 Evotec AG Composés hétérocycliques fusionnés de 2-cyanophényle, compositions et utilisations de ceux-ci
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
US20090317360A1 (en) * 2007-06-12 2009-12-24 Genelabs Technologies, Inc. Anti-viral inhibitors and methods of use
AU2008319308B2 (en) 2007-10-31 2013-01-31 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
WO2009058299A1 (fr) 2007-10-31 2009-05-07 Merck & Co., Inc. Antagonistes du récepteur p2x3 utilisés dans le traitement de la douleur
EP2234976B1 (fr) 2007-12-17 2013-04-10 F. Hoffmann-La Roche AG Nouvelles arylamides substituées pyrazole
ES2541662T3 (es) 2007-12-17 2015-07-23 F. Hoffmann-La Roche Ag Derivados arilamida sustituidos con triazol y utilización de los mismos como antagonistas de receptores purinérgicos P2X3 y/o P2X2/3
JP5318882B2 (ja) 2007-12-17 2013-10-16 エフ．ホフマン−ラ ロシュ アーゲー 新規なイミダゾール置換アリールアミド
BR122019016794B8 (pt) 2007-12-17 2021-07-27 Hoffmann La Roche derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso no tratamento de uma condição inflamatória e/ou autoimune
WO2009110985A2 (fr) 2008-02-29 2009-09-11 Renovis, Inc. Composés amides, compositions à base de ces composés et leurs utilisations
US20110237578A1 (en) 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
JP5592388B2 (ja) * 2008-10-31 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション 疼痛治療用のｐ２ｘ３受容体アンタゴニスト技術分野
EP2379518B1 (fr) 2008-12-16 2014-05-07 F. Hoffmann-La Roche AG Arylamides à substitution thiadiazole
EP2445868B1 (fr) 2009-06-22 2013-12-18 F.Hoffmann-La Roche Ag Amides biphényles utiles en tant que modulateurs des récepteurs p2x3 et/ou p2x2/3
CN102438989B (zh) 2009-06-22 2015-05-27 霍夫曼-拉罗奇有限公司 噁唑酮和吡咯烷酮取代的芳基酰胺
AU2011205283B2 (en) 2010-01-13 2014-07-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013009810A1 (fr) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Méthodes de traitement
WO2013173441A2 (fr) * 2012-05-16 2013-11-21 Glaxosmithkline Llc Inhibiteurs d'homologue d'activateur de zeste 2
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
DK2951177T3 (en) 2013-01-31 2018-06-14 Neomed Inst IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF
JP6544665B2 (ja) 2014-12-09 2019-07-17 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １，３−チアゾール−２−イル置換ベンズアミド
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
EP3793554A1 (fr) 2018-05-15 2021-03-24 Bayer Aktiengesellschaft Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses
MX2020012230A (es) 2018-05-15 2021-01-29 Bayer Ag Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas con la sensibilizacion de las fibras nerviosas.
EP3757103A1 (fr) 2019-06-27 2020-12-30 Bayer AG Analogues de 3-(5-méthyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}benzamide pour le traitement des maladies neurogeniques

Also Published As

Publication number Publication date
WO2016091776A1 (fr) 2016-06-16
PL3587417T3 (pl) 2022-06-13
CA2969952A1 (fr) 2016-06-16
PH12017501079A1 (en) 2017-10-18
PT3230281T (pt) 2021-08-19
CU20170077A7 (es) 2017-11-07
IL283979A (en) 2021-07-29
US10174016B2 (en) 2019-01-08
NZ733108A (en) 2022-03-25
SV2017005461A (es) 2018-04-30
EP3587417B9 (fr) 2022-03-30
NI201700073A (es) 2017-10-24
AR102948A1 (es) 2017-04-05
ES2882952T3 (es) 2021-12-03
MX2020005909A (es) 2021-10-28
JP2017537122A (ja) 2017-12-14
TW201629053A (zh) 2016-08-16
CR20210108A (es) 2021-04-27
HUE058009T2 (hu) 2022-06-28
HRP20220371T1 (hr) 2022-05-13
US10202369B2 (en) 2019-02-12
US10472354B2 (en) 2019-11-12
CR20170242A (es) 2018-02-02
IL269468B (en) 2020-06-30
EA032312B1 (ru) 2019-05-31
ES2908822T3 (es) 2022-05-04
IL269661B (en) 2020-07-30
MA50674A (fr) 2021-03-31
LT3230281T (lt) 2021-07-12
KR20230098368A (ko) 2023-07-03
IL269661A (en) 2019-11-28
AU2015359626A1 (en) 2017-06-29
SI3587417T1 (sl) 2022-04-29
US20200131169A1 (en) 2020-04-30
IL283979B (en) 2022-04-01
US11142523B2 (en) 2021-10-12
DK3230281T3 (da) 2021-08-16
EP3230281A1 (fr) 2017-10-18
PE20220253A1 (es) 2022-02-16
KR102548799B1 (ko) 2023-06-27
US20180093980A1 (en) 2018-04-05
AR119761A2 (es) 2022-01-12
CY1124486T1 (el) 2022-07-22
EP3230281B1 (fr) 2021-05-26
PL3230281T3 (pl) 2021-12-13
RS63014B1 (sr) 2022-04-29
RS62227B1 (sr) 2021-09-30
TWI716371B (zh) 2021-01-21
EA201891120A1 (ru) 2018-10-31
PT3587417T (pt) 2022-03-16
TW202130637A (zh) 2021-08-16
NZ761161A (en) 2024-04-26
MA41135B1 (fr) 2021-10-29
DOP2017000137A (es) 2017-07-31
JP6544665B2 (ja) 2019-07-17
UY36422A (es) 2016-06-30
HUE055290T2 (hu) 2021-11-29
SG10202012274RA (en) 2021-01-28
CY1125083T1 (el) 2023-06-09
MY192690A (en) 2022-09-01
HRP20211002T1 (hr) 2021-09-17
US20180118731A1 (en) 2018-05-03
IL275183B (en) 2021-06-30
CO2017005742A2 (es) 2017-09-20
IL269468A (en) 2019-11-28
EA201791261A1 (ru) 2017-12-29
BR112017012327A2 (pt) 2018-02-27
BR112017012327A8 (pt) 2021-02-23
US20230053411A1 (en) 2023-02-23
EP3587417A1 (fr) 2020-01-01
CN110256418B (zh) 2023-01-20
TN2017000244A1 (en) 2018-10-19
KR20170093203A (ko) 2017-08-14
IL252665B (en) 2019-10-31
CL2017001488A1 (es) 2018-02-23
ECSP17036253A (es) 2017-06-30
EA034273B1 (ru) 2020-01-23
LT3587417T (lt) 2022-02-10
MX2017007658A (es) 2018-08-01
CN107207507B (zh) 2020-11-06
AU2015359626B2 (en) 2020-07-23
JP6647371B2 (ja) 2020-02-14
SG11201704717VA (en) 2017-08-30
DOP2018000182A (es) 2018-09-15
CN107207507A (zh) 2017-09-26
BR112017012327B1 (pt) 2023-04-11
US20190185466A1 (en) 2019-06-20
IL269467A (en) 2019-11-28
DK3587417T3 (da) 2022-03-28
UA120382C2 (uk) 2019-11-25
IL252665A0 (en) 2017-08-31
IL269467B (en) 2020-08-31
TWI780562B (zh) 2022-10-11
JP2019059742A (ja) 2019-04-18
CN110256418A (zh) 2019-09-20
CU24411B1 (es) 2019-05-03
EP3587417B1 (fr) 2022-01-05
IL275183A (en) 2020-07-30
JOP20150301B1 (ar) 2023-09-17
SI3230281T1 (sl) 2021-08-31
PE20180227A1 (es) 2018-01-31

Similar Documents

Publication Publication Date Title
IL283979B (en) 3,1-thiazol-2-yl converted benzamides
FIC20230006I1 (fi) Vutrisiraani
DK3040326T3 (da) Haloolefin-baseret sammensætning
DK3006072T3 (da) Karadgang
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
FR3024363B1 (fr) Composition thermogelifiable
DE112015001664A5 (de) Betätigungsaktuator
KR20180084876A (ko) 내플라즈마성 부재
CL2017000639A1 (es) Composición
DK3110439T3 (da) Pcsk9-vacciner
DE112015005041A5 (de) Gargerätevorrichtung
DE102014000623A8 (de) Halbhohlnietelement
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
DK3217964T3 (da) Sammensætning
DK3009858T3 (da) Skyradar
FR3019552B1 (fr) Composition filmogene
DK3199160T3 (da) Vandig sammensætning
DE112015001633A5 (de) Betätigungsaktuator
DK3091875T3 (da) Vipbar taburet
FR3020039B1 (fr) Aerodyne
DE202014005655U8 (de) llluminationsvorrichtung
DE112015005055A5 (de) Gargerätevorrichtung
DE102014112481A8 (de) Axialfederanordnung
DE112014006499A5 (de) Umfüllbehälter
ES1098331Y (es) Abaco mejorado